The complaint filed against ARS Pharmaceuticals, traded under the ticker SPRY, alleges violations of the Securities Exchange Act of 1934. According to the court filings, the company issued false and misleading statements between March 9, 2026, and June 24, 2026. Plaintiffs contend that leadership was aware of complications regarding approval timelines for neffy—a key component of the company's commercialization strategy—but failed to disclose these obstacles to the market.

The DJS Law Group is currently organizing the class action and seeking potential lead plaintiffs to represent those who purchased shares during the specified class period. While the deadline to file for lead plaintiff status is today, the firm notes that individual investors do not need to assume this role to participate in a potential recovery. Interested parties are encouraged to contact David J. Schwartz at the DJS Law Group to review their eligibility and discuss the impact of the alleged misrepresentations on their holdings.